Related Experiment Videos
Clinical consequences of cytochrome P450 2C9 polymorphisms
Julia Kirchheiner1, Jürgen Brockmöller
1Department of Pharmacology, University of Cologne, 50931 Köln, Germany. julia.kirchheiner@uk-koelen.de
Clinical Pharmacology and Therapeutics
|January 8, 2005
Summary
Genetic variations in the cytochrome P450 (CYP) enzyme 2C9 gene significantly impact drug metabolism. CYP2C9 genotyping can guide personalized drug dosing, improving patient outcomes and treatment efficacy.
Area of Science:
- Pharmacogenetics
- Drug Metabolism
- Biochemistry
Background:
- The cytochrome P450 (CYP) enzyme 2C9 (CYP2C9) gene exhibits numerous inherited polymorphisms.
- Specific variants, such as R144C (*2) and I359L (*3), have significant functional impacts and high population frequencies.
Purpose of the Study:
- To review current knowledge on CYP2C9 genotypes, pharmacokinetics, and clinical drug responses.
- To explore the application of CYP2C9 genotyping for optimizing drug dosage adjustments in clinical practice.
Main Methods:
- Review of existing literature on CYP2C9 pharmacogenetics, pharmacokinetics, and clinical outcomes.
- Analysis of dose-related pharmacokinetic parameters (e.g., clearance, trough concentrations) in relation to CYP2C9 genotypes.
Main Results:
- Homozygous carriers of the CYP2C9 *3 allele exhibit significantly reduced drug clearance (<25% of wild type) for various medications.
- Heterozygous carriers (*1/*3 genotype) show intermediate reductions in clearance (40-75%).
- Pharmacogenetics-based dose adjustments correlate well with empirically derived doses for drugs like oral anticoagulants.
Conclusions:
- CYP2C9 genotype influences drug metabolism and response, supporting the use of genotyping for personalized medicine.
- Further research is needed to fully understand CYP2C9's role in endogenous molecule metabolism and drug toxicity.